Fig. 1

Shows the comprehensive analysis of CRGs in GBM. (A–F) UALCAN identified significantly differentially expressed CRGs (FDX1, LIPT1, CDKN2A, SLC31A1, PDHA1, GLS) in GBM.(G–H) GEPIA analyzed the prognostic significance of LIPT1 expression on recurrence-free survival (RFS) and overall survival (OS) in GBM patients. I, TIMER database analyzed the correlation between LIPT1 expression and CD8 + T cell infiltration in GBM.